Advanced Pharmaceutical Research & Formulation Technologies at Taj Medico

Every successful pharmaceutical product is supported by extensive scientific research, formulation development, analytical studies, process optimization, and manufacturing expertise. During the development of a new medicine, the knowledge generated along the way can contribute significantly to pharmaceutical science and help create better drug-delivery approaches for future products.

At Taj Medico, pharmaceutical research and formulation development are focused on applying established and emerging technologies to address challenges such as drug solubility, stability, bioavailability, dosing frequency, patient convenience, targeted delivery, and manufacturability.

Our formulation-development approach can encompass conventional dosage forms as well as specialized drug-delivery platforms. Depending on the characteristics of the active pharmaceutical ingredient (API), therapeutic objective, route of administration, and regulatory requirements, different technologies may be evaluated to achieve an appropriate product profile.

Microsphere Technology

Microsphere-based drug delivery is an important approach for developing controlled and sustained-release formulations. Microspheres are small spherical particles in which an active pharmaceutical ingredient can be dispersed, dissolved, entrapped, or encapsulated within a suitable polymeric matrix.

For long-acting injectable products, biodegradable polymers may be designed to gradually release the active ingredient after administration. Depending on the API, polymer system, formulation design, and intended clinical application, microsphere technology can potentially support prolonged drug release over weeks or months.

Important development parameters may include:

  • Particle-size distribution
  • Polymer selection and molecular characteristics
  • Drug loading and encapsulation efficiency
  • Initial burst release
  • In-vitro drug-release profile
  • Residual solvents
  • Sterility and endotoxin control
  • Reconstitution characteristics
  • Syringeability and injectability
  • Polymer degradation behaviour
  • Product stability

At Taj Medico, microsphere development can be approached through systematic formulation optimization, analytical characterization, process development, and scale-up considerations to establish a reproducible manufacturing process.

Liposomal Drug-Delivery Technology

Liposomal technology provides an advanced approach for modifying the delivery characteristics of pharmaceutical compounds.

Liposomes are microscopic vesicular structures generally composed of phospholipid bilayers surrounding an aqueous compartment. Their unique architecture allows liposomal systems to accommodate different types of active ingredients.

Hydrophilic compounds can potentially be incorporated within the aqueous phase, while lipophilic compounds may associate with the lipid bilayer.

Liposomal formulations can be investigated to address pharmaceutical challenges involving:

  • Poor aqueous solubility
  • Unfavourable pharmacokinetic properties
  • Drug instability
  • Distribution to non-target tissues
  • Dose-limiting toxicity
  • Rapid drug elimination
  • Need for modified or targeted delivery

Critical formulation attributes include liposome size and distribution, lipid composition, surface charge, morphology, drug-to-lipid ratio, encapsulation efficiency, leakage characteristics, chemical stability, and in-vitro release.

Taj Medico’s formulation-development activities can apply these principles when evaluating sophisticated parenteral and drug-delivery products.

Sustained and Extended-Release Formulation Technology

Sustained-release and extended-release technologies are designed to modify the rate at which an active pharmaceutical ingredient becomes available after administration.

Unlike conventional immediate-release dosage forms, modified-release products may maintain drug exposure for a longer period, depending on the pharmacokinetic properties of the drug and the formulation design.

Potential advantages include reduced dosing frequency, improved convenience, reduced fluctuations between peak and trough concentrations, and better adherence for medicines suitable for modified release.

Technologies used to achieve sustained release can include:

  • Hydrophilic matrix systems
  • Hydrophobic matrices
  • Polymer-coated pellets
  • Reservoir systems
  • Multiparticulate formulations
  • Osmotic drug-delivery principles
  • pH-independent release systems
  • Diffusion-controlled systems
  • Erosion-controlled systems

Polymer selection, API solubility, gastrointestinal behaviour, tablet geometry, coating characteristics, manufacturing conditions, and dissolution profiles are carefully considered during development.

Orally Disintegrating Tablet (ODT) Technology

Orally Disintegrating Tablets, commonly known as ODTs, are designed to disintegrate rapidly in the oral cavity when exposed to saliva.

The technology can provide a convenient dosage form for patients who experience difficulty swallowing conventional tablets and may be particularly useful when clinically appropriate for paediatric, geriatric, psychiatric, neurological, or dysphagic patient populations.

ODT development requires careful optimization because rapid disintegration must be achieved while maintaining sufficient mechanical strength for manufacturing, packaging, transportation, and handling.

Development considerations can include:

  • Disintegration time
  • Wetting characteristics
  • Tablet hardness
  • Friability
  • Mouthfeel
  • Taste masking
  • API particle size
  • Superdisintegrant selection
  • Moisture sensitivity
  • Packaging compatibility

Taj Medico can utilize appropriate excipient combinations and manufacturing processes to balance rapid disintegration with product stability and acceptable patient experience.

Inhalation Drug-Delivery Technology

Pulmonary drug delivery is an important pharmaceutical technology for medicines intended to reach the respiratory tract.

Inhaled formulations can provide direct delivery of active ingredients to the lungs and airways. For suitable therapies, this route can achieve localized drug concentrations while potentially limiting systemic exposure.

Inhalation technologies may include:

  • Dry Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Nebulized solutions
  • Nebulized suspensions
  • Unit-dose inhalation preparations

Developing an inhalation product requires considerably more than conventional formulation development. The interaction between formulation, device, particle characteristics, and patient inhalation behaviour can influence product performance.

Important characteristics may include aerodynamic particle-size distribution, delivered dose uniformity, fine particle fraction, moisture sensitivity, formulation-device compatibility, spray characteristics, and physical and chemical stability.

Taj Medico’s pharmaceutical development strategy can incorporate these considerations when developing respiratory drug-delivery systems for therapeutic areas such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Effervescent Formulation Technology

Effervescent technology provides a convenient approach for medicines designed to dissolve or disperse in water before administration.

Effervescent tablets generally contain carefully balanced acid and carbonate or bicarbonate components. When introduced into water, the reaction generates carbon dioxide and assists rapid tablet disintegration and dissolution.

The technology can be useful for selected APIs where rapid preparation, convenient administration, palatability, or alternative dosage presentation is desirable.

Development requires stringent control of environmental moisture because premature exposure to water can initiate the effervescent reaction.

Taj Medico’s development approach can include evaluation of moisture-sensitive manufacturing conditions, packaging systems, taste masking, dissolution performance, tablet hardness, and product stability.

Additional Pharmaceutical Technologies

Beyond these specialized platforms, Taj Medico can apply a broader range of formulation technologies according to the characteristics and intended use of individual pharmaceutical products.

Nanoparticle Drug-Delivery Technology

Nanoparticle technology involves the development of extremely small drug-carrier systems that may modify the solubility, dissolution, distribution, or release behaviour of active pharmaceutical ingredients.

Systems under pharmaceutical research can include polymeric nanoparticles, lipid nanoparticles, nanocrystals, and other nanoscale delivery platforms.

Development requires sophisticated characterization of particle size, polydispersity, surface properties, physical stability, drug loading, release behaviour, and potential particle aggregation.

Nanocrystal Technology

Poor aqueous solubility is a major challenge in pharmaceutical development. Drug nanocrystals can reduce API particle size to the nanometre range, substantially increasing surface area.

For appropriate compounds, this can improve dissolution characteristics and potentially enhance the performance of poorly soluble APIs.

Stabilizer selection, particle-size control, milling or homogenization conditions, agglomeration tendency, and physical stability are important development parameters.

Solid Dispersion Technology

Amorphous solid dispersion technology is another approach for addressing poorly soluble pharmaceutical compounds.

The API may be molecularly dispersed or incorporated into a polymeric carrier to maintain the drug in an amorphous or highly dispersed state.

Potential manufacturing approaches include spray drying and hot-melt extrusion, depending on the thermal characteristics and stability of the API.

The development process requires detailed investigation of API-polymer compatibility, glass-transition behaviour, recrystallization risk, moisture sensitivity, dissolution performance, and long-term stability.

Hot-Melt Extrusion Technology

Hot-Melt Extrusion (HME) combines pharmaceutical ingredients and suitable polymers under controlled temperature, pressure, and mechanical shear.

HME can be investigated for applications including solid dispersions, modified-release systems, taste masking, and specialized oral dosage forms.

Process parameters such as extrusion temperature, screw configuration, feed rate, residence time, torque, and cooling conditions can significantly affect the final product.

Pelletization and Multiparticulate Technology

Multiparticulate drug-delivery systems consist of numerous small drug-containing units rather than a single monolithic dosage form.

These may include:

  • Drug-layered pellets
  • Matrix pellets
  • Coated pellets
  • Mini-tablets
  • Granules
  • Multiparticulate capsules

Different populations of pellets can be coated with functional polymers to provide immediate, delayed, or sustained drug release.

Such systems provide considerable flexibility in designing sophisticated release profiles.

Enteric and Delayed-Release Technology

Some active ingredients require protection from the acidic environment of the stomach, while other medicines are intended to release primarily after reaching the intestine.

Enteric coating technology uses functional polymers designed to resist dissolution under acidic gastric conditions and dissolve at selected higher pH conditions.

Development involves careful evaluation of coating thickness, polymer composition, curing conditions, acid resistance, dissolution behaviour, and long-term coating stability.

Taste-Masking Technology

Unpleasant taste can significantly affect patient acceptability, particularly for oral liquids, chewable tablets, dispersible tablets, and orally disintegrating products.

Taj Medico can investigate different taste-masking technologies, including:

  • Functional polymer coating
  • Microencapsulation
  • Complexation
  • Flavour systems
  • Sweetener combinations
  • Lipid-based barriers
  • Granulation-based taste masking

The objective is to minimize immediate interaction between bitter APIs and taste receptors without adversely affecting drug release.

Solubility and Bioavailability Enhancement

Many pharmaceutical compounds have limited aqueous solubility, creating challenges during formulation development.

Depending on the API, different approaches can be evaluated, including particle-size reduction, salt selection, surfactants, cosolvents, complexation, lipid systems, amorphous dispersions, nanocrystals, and pH modification.

The appropriate technology is selected only after evaluating the API’s physicochemical and biopharmaceutical characteristics.

Liquid and Semisolid Formulation Technology

Taj Medico’s formulation-development capabilities can also encompass conventional and specialized liquid and semisolid dosage forms such as solutions, suspensions, emulsions, syrups, creams, ointments, and gels.

Development may involve optimization of viscosity, rheology, sedimentation behaviour, redispersibility, emulsion stability, preservative effectiveness, pH, drug release, microbial quality, and container-closure compatibility.

Sterile Injectable Formulation Technology

Parenteral products require particularly stringent formulation and manufacturing controls.

Development of sterile injectable products can involve solutions, suspensions, emulsions, or lyophilized preparations depending on API properties and intended administration.

Important considerations include:

  • Sterility assurance
  • Bacterial endotoxins
  • Particulate matter
  • pH and osmolality
  • API and excipient compatibility
  • Container-closure integrity
  • Extractables and leachables
  • Filter compatibility
  • Product stability

Manufacturing processes must be designed around appropriate sterile-processing and contamination-control principles.

Lyophilization Technology

Lyophilization, or freeze-drying, is particularly valuable for pharmaceutical compounds that do not have adequate long-term stability in aqueous solution.

During lyophilization, the product is frozen and water is subsequently removed under controlled vacuum through primary and secondary drying stages.

Cycle development may require investigation of freezing behaviour, collapse temperature, critical formulation temperature, primary drying conditions, residual moisture, cake appearance, reconstitution time, and product potency.

The objective is to develop a stable product that can be efficiently reconstituted before administration.

Aseptic Processing Technology

For sterile pharmaceutical products that cannot undergo terminal sterilization, appropriately designed aseptic processing becomes essential.

Aseptic manufacturing requires an integrated contamination-control strategy involving equipment design, environmental controls, personnel practices, sterilization processes, filtration, cleanroom operations, process simulation, and microbiological monitoring.

Advanced Coating Technology

Pharmaceutical coating serves both functional and aesthetic purposes.

Taj Medico can utilize coating principles for:

  • Film-coated tablets
  • Moisture protection
  • Light protection
  • Taste masking
  • Enteric release
  • Sustained release
  • Delayed release
  • Product identification

Successful coating development requires precise control over coating formulation, spray rate, atomization, inlet air, product temperature, drying efficiency, coating uniformity, and weight gain.

Fixed-Dose Combination Technology

Fixed-dose combinations (FDCs) contain two or more active pharmaceutical ingredients within a single dosage form.

Developing these products can be technically challenging because individual APIs may have different solubility, stability, compression, release, or chemical compatibility characteristics.

Formulation strategies can include physical separation, multilayer tablets, coated granules, multiparticulates, or specialized manufacturing sequences to minimize API interactions.

Bilayer and Multilayer Tablet Technology

Bilayer tablets provide an opportunity to physically separate incompatible APIs or create different drug-release profiles within a single tablet.

For example, one layer may provide immediate release while another provides extended release.

Development requires optimization of layer weight, compression force, interfacial bonding, hardness, friability, dissolution behaviour, and resistance to layer separation.

Pediatric and Geriatric Formulation Technology

Patient-centric pharmaceutical development increasingly considers the specific requirements of different age groups.

Taj Medico can investigate formulations such as dispersible tablets, oral liquids, mini-tablets, ODTs, powders for suspension, and other flexible dosage forms where appropriate.

Palatability, swallowability, dosing flexibility, excipient suitability, packaging, administration accuracy, and stability are important considerations.

Analytical and Formulation Characterization

Advanced drug-delivery technology must be supported by robust analytical science.

Depending on the dosage form, pharmaceutical development at Taj Medico can involve analytical techniques and studies covering:

Assay and impurity profiling to establish API potency and monitor degradation products.

Dissolution and drug-release testing to characterize immediate, delayed, sustained, or controlled-release behaviour.

Particle-size analysis for suspensions, microspheres, inhalation products, nanoparticles, and other particle-dependent formulations.

Solid-state characterization to understand polymorphism, crystallinity, amorphous content, and interactions between APIs and excipients.

Stability studies to understand how temperature, humidity, light, oxygen, and time affect pharmaceutical quality.

Container-closure compatibility studies to determine whether packaging appropriately protects the medicine throughout its intended shelf life.

Quality by Design and Process Development

Modern pharmaceutical development increasingly uses systematic scientific approaches rather than relying solely on trial-and-error formulation.

Quality by Design (QbD) principles can be applied to understand relationships between material attributes, manufacturing parameters, and final product quality.

Development can include identification of the Quality Target Product Profile (QTPP) and relevant Critical Quality Attributes (CQAs), followed by assessment of critical material attributes and critical process parameters.

Risk assessment, experimental design, process characterization, analytical development, stability evaluation, and scale-up studies can then contribute to the establishment of a robust manufacturing process.

Technology Transfer and Commercial Scale-Up

A successful laboratory formulation must ultimately be translated into a reproducible commercial manufacturing process.

Technology transfer therefore represents an important bridge between pharmaceutical R&D and routine manufacturing.

At Taj Medico, development considerations can extend from laboratory batches through pilot-scale evaluation and commercial-scale manufacturing.

Scale-up activities may assess equipment differences, mixing behaviour, granulation endpoints, drying characteristics, compression parameters, coating conditions, filtration processes, filling operations, hold times, yield, and other manufacturing variables.

The objective is to establish processes capable of consistently producing pharmaceutical products that meet predetermined quality specifications.

Taj Medico – Advancing Pharmaceutical Formulation Science

Taj Medico recognizes that pharmaceutical innovation involves more than discovering a new molecule. Significant opportunities also exist in improving how established and emerging therapeutic compounds are formulated, protected, delivered, released, administered, and manufactured.

Our technology-focused approach can encompass microspheres, liposomes, sustained-release formulations, orally disintegrating tablets, inhalation systems, effervescent formulations, nanoparticles, nanocrystals, solid dispersions, hot-melt extrusion, multiparticulate systems, enteric coatings, taste-masking technologies, solubility enhancement, sterile injectables, lyophilization, advanced coating systems, fixed-dose combinations, bilayer tablets, and patient-centric dosage forms.

By integrating formulation science with analytical development, process engineering, scale-up principles, quality systems, and regulatory considerations, Taj Medico aims to develop robust pharmaceutical products designed around quality, performance, manufacturability, stability, and patient needs.

Continuous research and scientific learning remain fundamental to this approach. Each formulation-development program generates knowledge that can strengthen future development activities and contribute to the advancement of pharmaceutical technology.